Abstract | OBJECTIVES: METHODS: A retrospective analysis was performed of the data of patients with ICC treated at our institution from March 2011 to January 2016. We used the Cox regression model and estimated the hazard ratios of potential prognostic factors for survival. RESULTS: CONCLUSIONS: Readily available clinical laboratory values reliably predicted the prognosis of ICC patients receiving GC therapy. If validated in other studies, these results may provide a useful tool for individual patient-risk evaluation and the design and interpretation of future trials.
|
Authors | Utako Ishimoto, Shunsuke Kondo, Akihiro Ohba, Mitsuhito Sasaki, Yasunari Sakamoto, Chigusa Morizane, Hideki Ueno, Takuji Okusaka |
Journal | Oncology
(Oncology)
Vol. 94
Issue 2
Pg. 72-78
( 2018)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 29017161
(Publication Type: Journal Article)
|
Copyright | © 2017 S. Karger AG, Basel. |
Chemical References |
- Deoxycytidine
- C-Reactive Protein
- Cisplatin
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bile Duct Neoplasms
(drug therapy, metabolism, pathology)
- Bile Ducts, Intrahepatic
(drug effects, metabolism, pathology)
- C-Reactive Protein
(metabolism)
- Cholangiocarcinoma
(drug therapy, metabolism, pathology)
- Cisplatin
(administration & dosage)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Female
- Humans
- Male
- Middle Aged
- Prognosis
- Proportional Hazards Models
- Retrospective Studies
- Gemcitabine
|